Digital Commons @ Assumption University
Honors Theses

Honors Program

2022

The Effects of Neuro-metals on Prion Disease Formation
Rebecca Choiniere

Follow this and additional works at: https://digitalcommons.assumption.edu/honorstheses

The Effects of Neuro-metals on Prion Disease Formation

Rebecca Choiniere

Faculty Supervisor: Anthony Sacino

Department of Biological and Physical Sciences

A Thesis Submitted to Fulfill the Requirements of the Honors Program at Assumption University

Spring 2022

2

Acknowledgements

A special thank you to my wonderful mentor, Professor Anthony Sacino, for providing
incredible support, advice, and motivation throughout the journey of writing this thesis.

A special thank you to Assumption University Honors Director Professor Mollie McGrath.

A special thank you to my Honors thesis defense committee Professor Nicolas Lessios and
Professor Benjamin Knurr.

A special thank you to Professor Colby Davie who served as interim honors program director
and also guided me through the honors program.

A special thank you to my family and friends who have supported me during my time at
Assumption.

3

Abstract
Prion diseases are transmissible spongiform encephalopathies that cause the neurons of
the brain to become damaged and die. Prions are a unique infectious particle as they are not like
bacteria or viruses since they lack nucleic acid. The PrPSc protein is responsible for the infections
caused by prion diseases and accumulates in the brain. PrPSc has a beta sheet conformation and is
responsible for disease in both humans and animals. Scientists have investigated prion diseases
in the laboratory to try and understand how these diseases spread and can infect different species.
Several of these studies have looked at the roles that essential metals play within the body and
their possible contribution to prion diseases. Metals are essential for life, as they act like
cofactors of many enzymes and are involved in cellular respiration and metabolism; transition
metals however are potentially harmful to cells as they participate in redox reactions, producing
reactive oxygen species (ROS), which can oxidize proteins, lipids, and nucleic acids. Metal
homeostasis may be induced and contribute to neurodegeneration. Reducing metal homeostasis
and limiting ROS and free radical production could serve as protection from the
neurodegeneration seen in prion diseases. This research paper utilized scientific literature to
examine the transition metals zinc, copper, iron, and manganese, pathology of prion diseases, the
effects that these metals have on disease formation, and potential treatment methods.

Historical Perspective
As early as 1868, a large number of cattle fell ill to a seemingly mysterious disease unlike
any infection seen before. These mysterious cattle deaths caused scientists to search for the
source of this infectious agent, which was later discovered to be a prion (proteinaceous infectious
particle), or simply, a misfolded protein. Although many symptoms and diseases had been
documented throughout history and later recognized as being caused by prions, the discovery of
Bovine Spongiform Encephalopathy (BSE), known to most as “mad cow disease,” gained much
public attention during the 1900s and sparked investigations into understanding the causative
agent of this disease and its mechanism of transmission (Parente, 2018).
Dating back as early as the 18th century, abnormal behaviors were recorded in Merino
sheep that caused the animals to excessively lick and scratch themselves against fences. Tikvah
Alper concluded from radiation-inactivation data that this infectious agent does not depend on
nucleic acid; this disease would come to be known as the prion disease scrapie (Parente, 2018).
Over the past few decades, scientists have further begun exploring the effects of misfolded
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proteins and have made numerous discoveries of types of prion diseases. Stanley Prusiner was
awarded the Nobel Prize in Physiology or Medicine in 1997 for his work on the “prion
hypothesis,” which was a revolutionary theory about a rare type of infection that concerns an
unusual protein, the prion. Unlike other infectious agents like bacteria or viruses, the prion does
not contain nucleic acid but contains protein, which puzzled many scientists. Ten years after
Prusiner and colleagues set out to find this agent, they were able to produce a sample preparation
derived from diseased hamster brains that contained the particle. Prusiner was the first to purify
this infectious agent and show that it was mostly composed of protein, and specifically
glycoprotein because it has a sugar attached. Prusiner developed the term “prion” in the early
1980s as a way to describe this agent that causes fetal brain disorders known as transmissible
spongiform encephalopathies (TSE); the word prion is the shorted form of “proteinaceous
infectious particle.” In 1984 the essential component of the prion was identified as the “prion
protein,” or PrP, which is encoded by the PRNP gene in the host genome (Parente, 2018).
Types of Prion Diseases and Characteristics
Prion diseases, or transmissible spongiform encephalopathies (TSEs) are rare progressive
neurodegenerative disorders that can affect both humans and animals. One of the more wellknown prion diseases is Bovine Spongiform Encephalopathy (BSE) also known as “mad cow
disease.” Chronic Wasting Disease (CWD), Scrapie, Transmissible Mink Encephalopathy, Feline
Spongiform Encephalopathy and Ungulate Spongiform Encephalopathy are the other thus far
identified animal prion diseases (Table 1).
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Table 1 Animal Prion Diseases
Animal Prion Diseases
Bovine Spongiform
Encephalopathy (BSE)

Affected Animals
-Cattle

Year Identified
1986

-Humans who consume meat
from cows with BSE can be at
risk for vCJD (human variant)
Chronic Wasting Disease
(CWD)

-Deer

1981

-Moose
-Elk
Scrapie

-Sheep

Recognized in 1772;
identified in 1942

-Goats
Transmissible Mink
Encephalopathy

-Minks

1947

Feline Spongiform
Encephalopathy
Ungulate Spongiform
Encephalopathy

-Domestic cats & cats in captivity

1990

-exotic animals

Late 1980s

Additionally, the five identified human prion disease are Creutzfeldt-Jakob Disease
(CJD), Variant Creutzfeldt-Jakob Disease (vCJD), Gerstmann-Straussler-Scheinker Syndrome,
Fatal Familial Insomnia, and Kuru (Table 2) (Prion Diseases, 2018).
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Table 2 Human Prion Diseases
Human Prion Diseases

Year
Identified

Common Symptoms

Creutzfeldt-Jakob disease
(CJD)

1920s

Personality changes, anxiety, depression, memory
loss, impaired thinking, blurred vision or blindness,
insomnia, difficulty in speaking & swallowing,
jerking movements, delirium, coma

Variant Creutzfeldt-Jakob
disease (vCJD)

1996

Similar to CJD with severe depression & intense
feelings of despair

Fatal Familial insomnia
(FFI)

1974

Sleep disturbance, psychiatric problems, weight loss,
and balance problems

Gerstmann-StrausslerScheinker syndrome (GSS)

1936

Progressive loss of coordination, dysarthria, loss of
coordination, difficulty walking & coordinating
voluntary movements (ataxia)

Kuru

Recognized in
1910s; official
reports 1950s

Body tremors, random outbursts of laughter, gradual
loss of coordination

Prions are a unique protein and when misfolded, form protein aggregates in brain tissue
that ultimately lead to neurodegenerative diseases in species. The PrPSc is the abnormal and
misfolded form of the PrP protein that builds up in diseased brains and infects both humans and
animals in a variety of diseases. In common bacterial or viral infections, the spreading or
transmission of a disease from one individual to another can occur through direct contact, usually
in the form of person-to-person contact or droplet spread, or spread indirectly through airborne
transmission, contact with contaminated objects, or through the consumption of contaminated
food or water (Higuera, 2017). The causes for human prion diseases are usually sporadic
(unknown) or genetic; there have also been cases where disease has been contracted by ingesting
contaminated tissues, or from exposure to contaminated PrP through hormone treatments or
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during surgical procedures. Transmission of diseases is usually contained to its own species
because of species or transmissions barriers; such barriers limit transmission of infection from
one species to another. However, there have been notable exceptions to this.
Usually, the species barrier results in a lack of propagation of the prion in a new host, but
the molecular mechanism that determines the permeability of the transmission barrier to a prion
in a particular host is not fully understood. Through the continuous study of prions, researchers
have identified important factors that appear to influence the permeability of the barrier. The
nature of the prion strain, homology (similar structure) between the primary amino acid
sequences of the donor and the host PrP, and the dose/amount of exposure route in the recipient
host are all factors that influence the cross-species transmission. Today, it is impossible to
predict the prion’s ability to propagate into a new host species and the only conclusion that can
be made about the species barrier is that it is extremely unpredictable.
Prion diseases are rare, with about 300 cases reported each year. Those who have a
family history of prion disease, have eaten prion infected meat, or have been exposed to
contaminated corneas or medical equipment are at risk for prion diseases. Some of the common
symptoms include rapidly developing dementia, difficulty walking, hallucinations, muscle
stiffness, confusion, fatigue, and difficulty speaking. Prion diseases can only be confirmed by
sampling brain tissue after death; however, MRI scans, samples of spinal fluid,
electroencephalograms, blood tests, and neurologic and visual exams can be used to help
diagnosis them (Higuera, 2017).
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Prion Diseases in Other Species
Prion diseases are found in many different species such as sheep and goats, and members
of the cervid family (deer, elk, moose, caribou). There are two forms of the scrapie disease:
classical (typical) and atypical. Classical scrapie is spread within the populations of sheep and
goats. Sheep infections are detected between the ages of two and five years old, whereas in
goats, infections are detected after six years of age. Manifestations include hunched posture, hind
limb ataxia with fore limb hypermetria, scratching, and wool loss. Atypical scrapie is believed to
occur spontaneously, or randomly, due to its unique molecular and phenotype characteristic
(Houston & Andréoletti, 2019). The clinical signs of classical scrapie include normal posture,
circling, scratching, ataxia, visible head tremor, and no wool loss (Cell Press, 2008). According
to the U.S. Department of Agriculture, approximately 30 percent of US sheep are genetically
susceptible to scrapie. Scientists have claimed there is no zoonotic potential, or potential for
animal infections to spread to humans. Oral inoculation experiments have been conducted
involving chimpanzees (Pan troglodytes), capuchin monkeys (subfamily Cebinae), cynomolgus
macaques (Macaca fascicularis), and woolly monkeys (Lagothrix sp.), and all appeared not
susceptible to the scrapie disease (Scrapie, 2020).
Chronic wasting disease affects many species of free range and captive wildlife
populations of mule deer, black-tailed deer, white tailed deer, black tailed deer, elk, moose, and
6reindeer throughout 24 US states and 2 Canadian providences, South Korea, and Europe, and
will likely spread to infect more animals in other areas of the world. In 1967, the disease was
first observed in cervids (mammals of the deer family) in captivity in Colorado and Wyoming
and was first thought to have been caused by nutritional deficiency or stress due to confinement.
The disease was classified as a spongiform encephalopathy in 1980 and is the most efficiently
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transmitted prion disease. To date, the origins of chronic wasting disease are still unknown, but
there is a hypothesis suggesting that the disease came from sheep scrapie transmission to cervids
or through spontaneous conversion of normal prion protein to the misfolded conformation. The
main symptoms of chronic wasting disease are excessive weight loss and isolation for the herd
population. Additional symptoms of rough hair, lower head position, and wider leg stance
appear, as well as polydipsia (thirst), polyuria (excessive urine output), bruxism (teeth grinding),
regurgitation, ataxia (lack of muscle control), and tremors. The behaviors of the cervids also
changes hyperphagia (the visual axis of eye deviates upward), repetitive and exaggerated leg
lifting, diminished alertness, and occasional aggressive behavior. The animals usually die within
18-24 months, by which time the body’s muscle mass has reduced and accounts for only about
20% of its maximum body weight (Legname, & Vanni, 2017).
Chronic wasting disease is the most efficiently transmitted prion disease. According to
the Centers of Disease Control and Prevention, in some locations where the disease is established
in free-ranging cervid populations, infection rates may exceed 10%, and in localized populations
more than 25%. In captivity infection rates are much higher with a rate of 79%, where nearly
four out of five cervids are infected within one captive herd (Centers for Disease Control and
Prevention, 2021). Zoonotic potential is believed to be low because experiments with
Cynomolgus macaques and transgenic mice that are expressing the human prion protein, have
shown low efficiency of human PrP conversion to the prion form after PrPCWD exposure
(Legname, & Vanni, 2017).
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Human Prion Disease
Creutzfeldt-Jakob disease (CJD) is a human neurodegenerative disease that causes
rapidly progressing dementia, ending in death within six to eight months of the symptom’s onset,
and about 70 percent of people die within one year (Creutzfeldt-Jakob Disease Fact Sheet, 2021).
This disease is rare, affecting about one in every million people throughout the world, and about
250 people in the United States each year. CJD cases have been grouped into three types:
familial, iatrogenic (infection through a medical procedure), and sporadic. The onset of
symptoms begins with changes in sleep patterns, weight loss, loss of appetite, and visual
disturbances such as double and blurry vision, or an unusual vision loss where the patient is not
aware he or she cannot see before the onset of dementia. Then memory loss, disorientation,
personality changes and psychosis, language disturbances, hallucinations, and muscle spasms
appear as the dementia progresses (Lutwick & Odle, 2020).
CJD is found primarily in adults ages 50-75. Familial CJD is inherited autosomal
dominantly, meaning either parent could pass on the disease. However, sporadic CJD is
responsible for about 85% of all CJD cases, and only age and PRNP codon-129 genotype have
been consistent risk factors (Lutwick & Odle, 2020). The cause or trigger of sporadic CJD is
known and is regarded as a spontaneous neurodegenerative disease that is most likely due to a
mutation of PRNP, the prion protein gene (Legname, & Vanni, 2017).
PrP Protein & Prion Pathology
Prion diseases are caused by one specific type of misfolded protein found in neurological
tissue of mammals. Prions are unique and transmit their misfolded shape onto normal variants of
the same protein, and then cause neurodegenerative disease in humans and animals. The exact
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function of Prusiner’s “prion protein,” which is encoded by the PRNP gene in the host genome,
is still unknown. There is speculation that the PrP protein plays a role in copper transport
between the cells of the central nervous system, that it might be important for cell
communication between nerve cells, or help protect neurons from becoming injured (Parente,
2018). It is known that PrPC is a glycosyl-phosphatidylinositol-anchored protein, meaning it can
be attached to the C-terminus of a protein during post translational modifications. PrPC is located
at both the presynaptic and postsynaptic sites throughout the central nervous system, and it is
especially abundant in the hippocampus (role in learning and memory), frontal cortex (higher
functions- decision making, problem solving, emotion regulations), and striatum (needed for
voluntary movement control) (Watt et al., 2012).
It is known that the pathological process occurs when PrP changes its conformation. The
“protein only” hypothesis also proposes that there are structural differences in PrPSc molecules
depending on the species; different species have slightly different structures of PrPSc. There has
also been evidence supporting that PrPSc changes conformations or changes shapes of the PrPSc
due to rotational changes of the molecule (Ma & Wang, 2014). In prion diseases, the prion
protein PrPC is converted to the alternative form PrPSc. This “protein only” hypothesis proposes
that the PrPSc form of the protein is the infectious agent in prion diseases, and it is able to
replicate itself by converting other PrPC to this PrPSc form (Wadsworth & Collinge, 2010). The
PrPSc induces conformational transformation of PrPC, creating a duplicate PrPSc, which causes a
chain reaction inducing further transformation of PrPC to PrPSc, and spreads to various parts of
the brain. Because PrPSc is not water soluble and resistant to degradation by protease, it
accumulates in the brain, leading to neuronal cell death (Gambetti, 2022). Over an extensive
period of time, PrPSc can lead to aggregates of protein that cannot be degraded by normal
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mechanisms and result in various diseases and affect the biological activity of organisms
differently.
The difference between the PrPC and PrPSc forms is in their monomer conformations and
aggregation states. Many mammalian species are affected by prion diseases. The PrP protein is
very similar in all mammals, but there are small differences in the PrP between the different
species. Because of these slight differences, it can be difficult in predicting the molecular basis
of prion propagation, as different strains lead to distinct phenotypes. There are a range of
mammalian PrPSc conformations possible, but only a select subset will be compatible with the
individual PrP; this means that an overlap of permissible PrPSc conformations between the source
and recipient and the variety in cellular mechanisms affect the prion propagation (Wadsworth &
Collinge, 2010).
Various clinical presentations can be observed from prion diseases in human. Progressive
dementia, cerebellar ataxia (uncoordinated muscle movement due to disease in the cerebellum),
pyramidal signs (spasticity, weakness, slowing of movements, hyperflexion), chorea
(involuntary, irregular, and unpredictable muscle movements), and seizures can be seen in
different combinations (Wadsworth & Collinge, 2010). Gliosis and histologic vacuolar changes
are observed in the brain. Signs and symptoms may develop months to years after initial
exposure to PrPSc (Gambetti, 2022).
Proteins PrPC and PrPSc differ in their tertiary structure (Figure 1). The normal PrPC form
of the protein consists of an amino acid chain with a portion arranged in an alpha helical
structure, which gives it a globular (bulblike) shape that is water soluble, and it can be broken
down by proteases enzymes. In contrast, the PrPSc form is arranged into beta-sheets, tends to
aggregate (stick together), cannot be dissolved in water, and is resistant to heat and breakdown
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by proteases. The PrPSc will bind to alpha-helical PrPC and convert it into the PrPSc beta-sheet
confirmation; this causes a chain reaction where large amounts of PrPSc build up resulting in
brain tissue damage and the spongy appearance of spongiform encephalopathy (Parente, 2018).

Figure 1 The normal PrPC versus the abnormal PrPSc (Molecular Structure of Normal Protein vs
Prion, 2017).
Scientists are still working to uncover information about the causes of the disease
pathology, protein misfolding, and potential therapeutic strategies of prion disease. One area of
research that has attempted to address these questions is the relationship between prions and
specific metals. In recent articles, scientists have developed the term “neuro-metals” to describe
trace elements that play a significant role in brain development and function; these metals can
exist at different concentrations and distributions throughout the various regions of the brain.
There is evidence suggesting that PrPC has the ability to bind metals and plays crucial roles in the
maintenance of metal homeostasis. Zinc, copper, iron, and manganese are examples of these
neuro-metals and their effects on PrPC and PrPSc are being investigated. These metals are
important for function because they help with many biological processes, and they also have the
ability to interact with oxidation-reduction reactions; continuous oxidative-reduction reaction can
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create free radicals, which are harmful. With the “prion hypothesis,” it is not clear whether PrPC
is losing part of its normal protective function, or if the conformational change is causing it to
gain a toxic function. There is reason to believe that these neuro-metals affect the function and
shape of PrP, and their creation of free radicals can also contribute to infection. Because the
mechanism for PrPC conversion to infectious PrPSc is not fully understood, there is hope that
studying the way neuro-metals interact with PrP can help to understand its way of infection and
create potential treatments.

Human Body Elements & Metal
There are a significant number of chemical elements that are essential for life with known
functions, but there are also several elements considered ‘non-essential,” as their functions and
relevance are uncertain. There are many important elements that the human body needs in order
to survive and allow for biochemical processes to occur. Some of these important elements are
metals such as Na, K, Mg, Ca, Fe, Mn, Co, Cu, Zn and Mo, which keep the body functioning,
and are found in different amounts in the average person (Table 3) (Maret, 2016).
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Table 3 Typical amount of each element found in the body of a 70kg person
Element

Median Amount

Ca

1000g

K

140g

Na

100g

Mg

30g

Fe

5g

Zn

2g

Cu

100mg

Mn

16mg

Mo

5mg

Co

2mg

Elements in the body can be divided into two categories: abundant and trace. Elements that are
present in smaller amounts (typically these amounts are not precisely known) are called trace
metals. The trace metals zinc, copper, iron, and manganese are necessary for function and growth
of the brain. The brain barrier system (blood brain and blood cerebrospinal fluid barriers) is
responsible for regulating the transport of these trace metals into the brain (Enelhart & Sorokin,
2009).
Zinc
Zinc is a chemical element with symbol Zn and atomic number 30 on the periodic table.
With an atomic weight of 65.409 μ, zinc has a simple hexagonal structure and grey color in its
solid form. Zinc has several functions as it has been shown to have catalytic, structural, and
regulatory functions. In 1869, it was discovered that zinc played an important role in the growth
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of fungus, and in 1961 its importance for human growth also became clear as hypogonadism and
dwarfism were reported in those living off of a diet low in zinc, that consisted of mostly bread,
potatoes, and milk (Roohani et al., 2013).

Zinc is the second most abundant trace metal in the body after iron. It is absorbed in the
small intestine and is secreted in the gut and on average, 33% of zinc intake is absorbed in
humans (Saper & Rash, 2009). There are at least 10 zinc transporters (ZnTs) and 15 zip
transporters in cells whose distributions are affected by zinc distributions in the body, and they
serve opposite roles in zinc homeostasis (Roohani et al., 2013).

The brain has the highest concentration of zinc relative to other organs in the body (150
μM), and it is found mainly in specific axons of the hippocampus that are mossy fibers, which
suggests that it plays a role in neurotransmission (Treiber, 2005). Zinc also has antioxidant
properties as it acts as a co-factor for enzymes involved in the functioning of the antioxidant
defense system. Additionally, zinc protects against oxidative damage and reduces hydroxyl
radicals (Marreiro et al., 2017). It is suggested that the daily intake for a human that is 50kg is 711mg (Wada, 2004).

Copper
Copper is another chemical element that is essential to the body. The symbol for copper
is Cu, and it lies in group 11 of the periodic table, with atomic number 29. This reddish,
extremely ductile metal is a great conductor of electricity and heat, and it has an atomic weight
of 63.546 µ (Britannica, 2020). Copper is involved in energy production, iron metabolism,
neuropeptide activation, connective tissue synthesis, and neurotransmitter synthesis. Copper also
regulates gene expression, brain development, and immune system function (U.S. Department of
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Health and Human Services, 2022.). In the nervous system, copper is also required for the
formation of myelin (Bost et al., 2016).
Although there have been inconsistent studies to derive the suggested daily intake, it has
been shown that a daily intake below 0.8 mg/day leads to a net copper loss, and net gains are
observed with a daily intake of an amount above 2.4 mg/day. Dietary copper deficiencies can
have adverse effects during all stages of life; in utero, deficiencies can result in impaired
development of the cardiovascular system, bone malformations, as well as neurological and
immunological abnormalities. In adults, deficiencies are associated with alterations in cholesterol
metabolism. Additionally, copper in high level can be toxic and lead to reactions resulting in
oxidative cell damage and cell death (Bost et al., 2016). The brain is one of the most energy
demanding tissues of the body, so it requires a lot of energy. About 95% of the total ATP in the
brain is generated in the mitochondria, so mitochondrial efficiency is important for the brain.
Cytochrome c oxidase is a member of the super-family of heme-copper containing oxidase that
catalyzes the last step of the mitochondrial respiratory chain, making copper an essential
component of brain metabolism (Scheiber et al., 2014).
Iron
Iron is a chemical element with symbol Fe and atomic number 26. It is the first metal in
group 8 of the periodic table with an atomic mass of 55.845 μ. By mass, iron is the most
common element in earth and forms much of the Earth’s crust. Inorganic iron plays an important
role in hemoglobin synthesis and hemoglobin formation as well as oxygen transport. Although
iron is an abundant element on earth, it forms oxides when in contact with oxygen, making it
highly insoluble and not available for uptake by organisms. In humans, iron exists in complex
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forms bound to protein (hemoprotein) as heme compounds (hemoglobin or myoglobin), heme
enzymes, or nonheme compounds (flavin-iron) (Abbaspour et al., 2014).
Ranging from 5-35%, depending on circumstances, iron absorption is typically low and
occurs mostly in the duodenum and upper jejunum (Abbaspour et al., 2014). It is then transferred
across the duodenal mucosa into the blood, and then transported by transferrin to cell or bone
marrow for the production of red blood cells. Iron balance is mainly regulated at the point of
absorption since the body lacks a defined mechanism for its active excretion. Also, the
circulating peptide hormone hepcidin is secreted by the liver and acts a negative regulator of iron
entry in the plasma (Abbaspour et al., 2014). Iron is essential because of its role in neurological
function as it contributes to oxidative metabolism, and due to the fact that it is a cofactor in the
synthesis of neurotransmitters and myelin. There have been many cases studied where brain iron
concentration has been seen to increase with age, and with diseases such as Alzheimer’s and
Parkinson’s (Piñero & Conner, 2000).
Iron also plays a role in oxidative metabolism. Cellular damage can be induced through
hydroxyl radical production, causing the oxidation and modification of proteins, lipids,
carbohydrates, and DNA, if abnormal homeostasis of iron occurs. Additionally, iron is a cofactor
in the synthesis of neurotransmitters and myelin (Ward et., 2014).
Manganese
The chemical element manganese has the symbol Mn and atomic number 25. This hard
brittle, and silvery metal has an atomic mass of 54.94 µ and is found in small amounts
throughout the body. Manganese is involved in development, reproduction, antioxidant defense,
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energy production, immune response, and regulation of neuronal activities. It is also involved in
the synthesis and activation of various enzymes (Li & Yang, 2018).
Absorption occurs by ingestion, inhalation, and dermal permeation as it is absorbed in the
gastrointestinal tract and lungs, and then it is distributed to different tissues by blood circulation
(Pan et al., 2018). The absorption and excretion of manganese is under constant homeostatic
control to ensure a stable level is maintained within the body (Aschner & Ascher, 2005).
Manganese deficiencies are rare, yet they can occur; manganese poisoning is also possible if
there is overexposure to the metal. Those with iron deficiencies are at an increased risk of
manganese poisoning because manganese absorption in the gastrointestinal tract increases under
low iron conditions (Pan et al., 2018). Additionally, manganese deficiencies have been
associated with skin lesions and bone malformations (Crossgrove & Zheng, 2004). The daily
intake for manganese depends on development and lactation stages and are as follows:
Table 4 Suggested daily intake of manganese U.S. Department of Health and Human Services.
(2022).
Age

Male

Female

Pregnancy

Lactation

Birth to 6
0.003 mg
months
7–12 months 0.6 mg

0.003 mg

1–3 years

1.2 mg

1.2 mg

4–8 years

1.5 mg

1.5 mg

9–13 years

1.9 mg

1.6 mg

14–18 years

2.2 mg

1.6 mg

2.0 mg

2.6 mg

19–50 years

2.3 mg

1.8 mg

2.0 mg

2.6 mg

51+ years

2.3 mg

1.8 mg

0.6 mg
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Manganese is part of the antioxidant enzyme superoxide dismutase (SOD), and antioxidants help
protect against free radicals that can damage cells. Accumulation of manganese in the brain can
alter neurotransmitters systems and their activity in the brain (Balachandran et al., 2020).
Oxidative Stress
Oxidative stress is an important concept as it plays a role in brain aging,
neurodegenerative diseases, and conditions such as ischemia. During oxidative stress, free
radicals can cause damage to cells, or even cause cell death. With neuro-metals, there is potential
that these transition metals can contribute to reactions causing reactive oxygen species and free
radicals, which cause oxidative stress. There are many oxidative processes in the body for
everyday metabolism and immune defenses; these processes are balanced by antioxidant systems
(Koivula & Eeva, 2010). Many chemical reactions involve the transfer of electrons, and
specifically, the oxidation-reduction reaction (known as a redox reaction). Oxidation and
reduction refer to a change in oxidation number; oxidation involves an increase in oxidation
number, and reduction has a decrease in oxidation number. Redox reactions are commonly
defined to be a reaction in which one species loses electrons, while another one gains electrons
(Redox, 2022). Redox reactions are important for biological systems because they are the
principal sources of energy on this planet. Oxidation of molecules through removal of hydrogen
or combing with oxygen can liberate large quantities of energy (What are redox reactions
biology, 2022).
Oxidizing agents have the ability to oxidize other substances, meaning that they remove
electrons from another substance; it is also known as an electron acceptor because it “accepts”
electrons. The reducing agents have the ability to reduce other substances, as they transfer
electrons; often called electron donors. Cellular respiration is an example of a redox reaction that
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is important to the body and energy. In this process, glucose is oxidized, and oxygen is reduced
(Redox, 2022). The oxidized and reduced forms of the same molecule are together called a redox
couple, and redox cycling occurs when the reduction and oxidation reactions are repeatedly
coupled. In theory, all redox active compounds could participate in redox cycling, but the extent
of the cycling is dependent on the local conditions and state of the involved molecules (Arnér,
2012). Redox cycling can lead to disproportionate consumption of O2 and cellular reducing
substances and formation of oxygen species, which cause oxidative stress (Redox, 2022).

Studies have indicated that transition metals act as catalysts in the oxidative reactions of
biological macromolecules. Oxidative stress can be caused by metals increasing the formation of
reactive oxygen species (ROS). Reactive oxygen species are highly reactive forms of O2. The
ROS are byproducts of normal oxygen metabolism and are present at low level in normal cells. If
these reactive oxygen species overwhelm the cells’ intrinsic antioxidant defenses, it results in the
condition known as “oxidative stress” (Nuran et al., 2001). Redox active and redox- inactive
metals can increase the production of ROS, like hydroxyl radicals (HO-), superoxide (O2-), or
hydrogen peroxide (H2O2) (Nuran et al., 2001). The redox-active metals undergo redox-cycling,
while redox-inactive metals deplete the cells’ major antioxidants. With the production of the
ROS, antioxidants are incapable of defense against the growing amounts of free radicals
(Koivula & Eeva, 2010). The ROS can cause lesions in cells to lipids, proteins, and DNA,
making the cells dysfunctional. This suggests that the metal induced oxidative stress in cells
could be responsible for the toxic effect of heavy metals (Nuran et al., 2001). Iron and copper are
two examples of metals that are redox-active metals and can form these reactive oxygen species.
Zinc and manganese are examples of redox-inactive metals and can influence redox homeostasis.
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Methodology

The goal of this literature review was to investigate the effects of metals in the body and
their role in prion diseases. From reading published literature, it is evident that transition metals,
specifically zinc, copper, iron, and manganese, have been shown to bind to PrP and affect its
conformation, abilities to bind other molecules, or impact the uptake of other molecules in the
brain. Some articles have created the term “neuro-metals” for these metals. Studies were
examined from 2000 through 2022 and the variety of implications these metals have on PrP and
aggregation formation were studied. Some newer studies on developing ideas for
treatments/therapeutic techniques were also examined. The Assumption University library
databases were utilized to locate information, as well as Google Scholar, and PubMed.
Effects of Neuro Metals on PrP
Although the exact function of PrPC remains unclear, it possesses the ability to bind to
various neuro-metals including copper, zinc, iron, and manganese. There are four complete
copies of the octapeptide repeat (PHGG(G/S)WGQ), which can bind copper and zinc, on the
amino terminal half of the PrPC. This octapeptide repeat has been shown to play a large role in
the PrP ability to bind metals and has been affected by metals as they are not in homeostasis
(Watt et al., 2012).
There are two possible pathogenic pathways of prion diseases; there is the possibility that
there is a loss of normal protective function of PrP, or there is the possibility that there is a gain
of toxic function of PrP. Studies involving these neuro metals have looked into the ways in
which the PrP and disease formation are affected by zinc, iron, copper, and manganese and the
support of these two different hypotheses.
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Zinc:
A study by Watt et al. published in Nature Communications showed that the prion protein
facilitates uptake of zinc into neuronal cells, which suggests that alterations in the cellular prion
protein-mediated zinc uptake may contribute to neurodegeneration in prion and other
neurodegenerative diseases.
Two zinc selective fluorescent dyes, Zinpyr-1 and Newport Green, were used to show for
the first time that PrPC mediates the uptake of zinc into neuronal cells, showing that the zinc
uptake is mediated by AMPA receptors containing GluA1 and lacking GluA2 subunits. When
PrPc was mutated, or cells were infected with the PrPSc, zinc uptake was disrupted,
suggesting that the reduction in uptake of zinc contributes to the neurodegeneration that is
commonly associated with prion diseases (Watt et al., 2012). Zinc uptake was reduced in the
presence of mutated PrPC and PrPSc, so lower levels of zinc are observed in brains when PrPC
does not function properly. This would suggest that zinc uptake distribution has some sort of
negative effect on the functions of PrPc.
The intracellular protein tyrosine phosphatase is sensitive to zinc and has increased
activity in its presence. In mouse cells expressing PrPSc, there was a significant reduction of
phosphatase activity as compared with the uninfected cells; this indicates that the uptake of zinc
by PrPC has a downstream effect on cellular processes. This was confirmed by
measuring tyrosine phosphatase activity in the brains of wild-type and PrPC null mice. Higher
levels of tyrosine phosphatase activity were seen in the PrPC null mice compared to the wild-type
and age matched control mice. This indicated that PrPC is involved in the physiological
homeostasis of neuronal zinc (Watt et al., 2012).
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Zinc levels have been shown to be reduced in prion disease infected brains. Zinc uptake
was measured in mouse ScN2a cells infected with scrapie, compared to uninfected controls
following exposure to exogenous zinc. There was an increase in zinc uptake in the uninfected
cells; however, there was no increase measured in the scrapie infected controls. This shows that
PrPC mediated zinc uptake is lost in cells expressing prion disease and the associated mutants of
PrPC upon conversion of PrPC to PrPSc. Observations from this study would suggest that the loss
of normal functions of PrPC would contribute to prion disease pathogenesis (Watt et al., 2012).
Pan et al. conducted an experiment to study the effect of zinc on aggregation and
conformational change of PrP. Thioflavin T binding assays, Sarkosyl-soluble SDS-PAGE, and
transmission electron microscopy showed that in the absence of zinc, the aggregation of wildtype PrP undergoes the steps of amorphous aggregates, profibrils, mature fibrils, and fragment
fibrils. The fibrils are formed and then resistant to degradation. When the molar ratio of Zn2+ to
PrP was 9:1, the aggregation of wild-type PrP undergoes a different pathway in which the wildtype PrP forms oligomers quickly and then short-rod aggregates, demonstrating that this change
causes the steps of aggregation to change (Pan et al., 2011). With no concrete mechanism for
pathogenesis established, these results show that when zinc is in a higher ratio, it changes the
pathway and formation of PrP aggregates.
Copper:
A study by Younan et al. published to the Journal of Microbiology indicated that copper
ions induced secondary structural changes and reduced folding stability on the prion
protein. PrPC is concentrated at presynaptic membranes where copper ions are also highly
localized and free Cu2+ levels at the synapse may reach levels as high as 20 µm during neuronal
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depolarization (Younan et al., 2011). This study looked to investigate the direct structural effect
Cu2+ has on the prion protein.
To see if Cu2+ affected the folding stability of PrPC, the chemical denaturant urea was
used to monitor Cu2+ and app-PrP(23–231) levels. This app-PrP(23-231) is a section of the
octarepeat region of the prion protein that binds copper. The CD (Circular Dichromism is an
absorption spectroscopy method based on differential absorption of left/right circularly polarized
light) signal at 225nm was used to measure the alpha-helical content over a range of urea
concentrations. The urea concentration at the midpoint of folding was found to be 5.79 +/-0.04
M at pH of 7.5 for the apo-PrP(23–231), which also aligned with other studies. This destabilized
the native fold of the Cu2+ binding to PrP(23–231). The urea unfolding was also shown to be
reversible through a series of serial dilutions of copper preparations from a PrP sample with 10
M urea to 1 M urea). Additionally, using mouse PrP, it was shown that the PrPC domain has an
irregular structure in the absence of Cu2+. In the absence of copper, there is a single negative CD
band at 198nm, while there is a reduction in the band when Cu2+ was added to the mouse PrP(23126). This suggests a loss of irregular structure. These studies have been limited due to the
flexible nature of the Cu2+ binding site on the PrPC which has hampered crystallographic studies,
while the paramagnetic nature of Cu2+ has restricted NMR studies (Younan et al., 2011).
A recent study by Chi-Fu et al. showed that copper induced structural conversion of the
prion protein. This study used recombinant, full length, human PrP to perform a variety of tests
to better understand the effect copper has on the prion protein (Chi-Fu et al., 2016). Proteinase K
sensitive PrP and a fluorescence-based single-molecule proteinase K resistant assay was used.
The PrP proteinase K sensitive PrP was biotinylated and then covalently immobilized and then
incubated without Mn or copper ions. The samples were treated with proteinase K, which would
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not break down the PrP if it was converted to the proteinase resistant form. The full length PrP
(23-231) incubated with the copper converted to a proteinase resistant form. Globular PrP that
lacked the unstructured N terminal region (PrP (90-231)) was still sensitive to the proteinase
digestion in both the absence and the presence of copper. This showed that the monomeric PrP
proteinase resistant formation requires both intrinsically disorder N terminal region and Cu2+
ions (Chi-Fu et al., 2016).
PrP aggregation was monitored using ThT fluorescence (commonly used probe to
monitor in vitro amyloid fibril formation) intensity and in vitro seeding assay to test whether PrP
exposed to divalent metal ions forms seeds that template aggregation. There are many theories
about how PrPC converts to PrPSc, and one of them is the seeding hypothesis. In this hypothesis,
the protein is unable to undergo structural alteration and polymerization on its own, and the
addition of a small aggregate or seed is needed for the conversion process to be initiated. Early
studies by Kocisko et al. showed that once PrPSc was added to recombinant PrP, the conversion
process was initiated (Hesketh et al., 2011). In this particular study by Chi-Fu et al., the PrP (23230) with copper began forming seeds (15-25hrs) and aggregates, and the PrP (23-230) in the
absence of copper only started to form seeds after 55 hours. And PrP (90-230) showed no seed
formation after 95 hours.
The cytotoxic nature of Cu2+ induced PrP amyloids was also demonstrated using slices of
brain tissue from young mice and PrP (23-230) pre exposed to Cu2+ and PrP (23-230) with no
metal exposure. Glial fibrillary acidic protein (GFAP) (indicator of astrocytic activation during
neuroinflammation) and the expression of protein kinase δ (oxidative stress sensitive and
activation shown to induce neuronal cell death) were measured. Western blot analysis indicated
that PrP Cu 2+ had higher levels of GFAP and PKC-δ (PKC-δ) than its control (Chi-Fu et al.,
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2016). This indicates that oxidative stress is occurring, and astrocytes are activated because there
is neuroinflammation when copper is present.
Iron:
Studies have indicated that most-regulation of iron metabolism in sporadic-CreutzefeldtJakob disease and scrapie infected animal brains show a redox-iron in prion disease
pathogenesis. This is an important observation given its highly toxic nature and involvement in
other neurodegenerative conditions of protein misfolding like in Alzheimer’s and Parkinson’s
diseases. This has formulated the idea that brain iron gets out of the range of homeostasis as a
result of massive neuronal death, but more evidence suggests that iron imbalances precede
neuronal degeneration and are the trigger for neurotoxicity.
Published in the Neurobiology of Disease journal, research by Singh et al., was
conducted by looking at iron imbalances in prion disease infected tissues. Frozen human brain
tissues from the frontal cortex of sCJD (CJD+) and age matched cases of dementia (CJD-)
ranging in age from 37-80 years old, with most in the 67-80 year range were studied. The
interval from the appearance of clinical symptoms to death ranged from 1-24 months in CJD
versus 2-4 months in CJD+. Control and prion infected hamster spinal cord samples were also
used (Singh et al., 2012).
The tissues from the frontal cortex of the sCJD (CJD+) and non-CJD dementia (CJD-)
were homogenized in a buffer containing a lysis buffer supplemented with 1% SDS and were set
at room temperature or were boiled for 10 minutes, because most iron binding proteins release
associated iron after boiling. The unboiled CJD+ and CJD- revealed similar iron content. The
boiled samples however were quite different; the CJD- released 68% of the associated iron while
CJD+ lost minimal amounts. Directly compared, there was 183% more iron in the CJD+ samples
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relative to the CJD- samples. These results were similar to those with Alzheimer’s disease, which
is known to accumulate iron in the brain. It was demonstrated that iron is sequestered in SDSstable protein complexes in sporadic-Creutzfeldt-Jakob disease brains, which creates a
phenotype of iron deficiency. This is due to a change in the iron storage protein ferritin that
becomes aggregated, detergent-insoluble, and partitions with denatured ferritin (Singh et al.,
2012).
Lumbar spinal cord tissue of scrapie infected hamsters displayed a similar phenotype.
The iron uptake protein transferrin (Tf) is upregulated in scrapie infected spinal cord tissue and
increases with disease progression. Samples were harvested at 28, 42, 55, and 70 days post
inoculation, homogenized in lysis buffer, and analyzed by Western blotting. The levels of PrP
significantly increased after 55 days post inoculations and Tf also increased. After quantification
by densitometry, it was revealed that PrP increased by 193%, and Tf by 385% after 70 days post
inoculation relative to 28 days post inoculation. Iron deficiency continues to increase until the
end stage of disease, despite minimal changes in brain iron levels. There is a direct correlation
between Tf and PrPSc which suggests sequestration of iron in dysfunctional ferritin that either coaggregates with PrPSc or is rendered dysfunctional by PrPSc through an indirect process (Singh et
al., 2012).
A study conducted by Pino et al. in 2017 looked to investigate how dietary iron
restriction influences brain ferritin, the main iron storage protein, and dopamine metabolism in
three regions of the brain, and how altered iron and dopamine metabolism can affect the
expression level and solubility of PrPC.
Three-month-old male mice were studied with half receiving a normal diet containing
45ppm of iron and half with a restricted iron diet containing 3ppm of iron for four weeks. The
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mice on the iron restricted diet showed reduced ferritin in serum in the liver, and hippocampus,
compared to the control group. The ferritin (which is a blood protein that contains iron) level of
the mice on the restricted diet was increased in the striatum compared to the control group.
Thiobarbituric acid was used to evaluate the extent of lipid peroxidation and showed that
although the ferritin level in the iron restricted mice was decreased, there was a higher level of
lipid peroxidation compared to the control group.
These observations would suggest that there is an increase in oxidative stress in the
hippocampus under iron deficient conditions. Western blots were used to investigate dietary iron
deficiency on the expression of PrPC levels. There was a significant increase in PrPC levels in the
striatum in the iron deficient group. Other regions did not produce significant effects of PrPC
levels (Pino et al., 2017).
Manganese:
Research conducted by Paul Davies and David Brown investigated sporadic forms of
prion diseases and environmental risk factors by using extracts of the prion protein from soil
matrices. Previous studies have suggested that environmental manganese is a possible risk factor
for prion diseases, and Davies and Brown extracted the prion protein from soil matrices and
showed that when exposed to manganese, there is a dramatic increase in prion protein survival
(∼10 fold) over a two-year period (Davies & Brown, 2009).
The two most commonly used model soil systems for protein-soil interaction studies are
montmorillonite (mte) and kaolinite (kte). To investigate whether metals play a role in stabilizing
PrP, copper and manganese were added to the soils along with wild-type and mutant PrP. The
prion protein was extracted from the clay by electrophoretic desorption and Western blot
analysis. After a 2-year incubation of the clay, PrP was found to survive better when in the
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presence of metals, specifically manganese. According to the study, there is around half as much
prion protein recovered from the clay with copper (n = 3, p<0.001) and around 6 times less
protein from the clay with no metals present (p<0.001) relative to the manganese condition
(Davies & Brown, 2009).
To test the infectivity, a cell cultured based assay system was utilized in which uninfected
cells (SMB-PS), were transfected with PrP. Under infected conditions, PrP infection was only
seen at the 1∶10 dilution, as the higher dilutions did not result in PK resistant bands (showing PrP
infection). This was repeated with the presence of 50 µM MnSO4. Results of the repeat
experiment show the PK bands indicating infection at 1:10, 1∶102 and 1∶103 dilutions. The
infectivity of the SMB extract was increased by 100 fold by the presence of manganese. These
results demonstrate that manganese enhances prion infection. Showing that manganese is a risk
factor for the survivals of PrPSc in the environment as well as aiding in its transmissibility. This
suggests that PrP and manganese separation may make the PrP less infectious (Davies & Brown,
2009).
In an experiment by Hesketh et al., an assay based on exposure of recombinant PrP to
manganese was used. A turbidity test was used to test the effect of the Mn-PrP seed in the
polymerization of PrP, and it was found that increasing the concentration of the seed increased
the rate of polymerization and the maximum amount of polymerization with manganese present.
In the absence of the seeding protein, there was no polymerization of the protein (Hesketh et al.,
2012).
A series of tests using mutants was also done: mutants included the N terminus half PrP
(23-112), the C terminus half PrP (112-231), extended mutant with N terminus PrP (23-171),
mutant lacking N terminus PrP (90-231), mutant with part of N terminus and first helical domain
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PrP(90-171), mutants lacking palindromic repeat region (112-119) and mutant with histidines at
positions 95 and 110 replaced with alanine residues. The two mutants PrP (23-112) and (112231) were unable to generate seeds as well as the mutant without the manganese binding
site. This showed that the minimum domain for PrP seed formation was 90-171 (Hesketh et al.,
2012). As scientists still do not know the mechanism of prion pathogenesis, this experiment has
helped to show that PrP (90-171) is needed and crucial for seed formation. Since seeds were not
able to generate without the manganese present, it also illustrates that manganese plays a role
also in the ability for seeds to form.
Treatments
Currently there is no cure for prion diseases, but various studies are being conducted
targeting a variety of possibilities. Several of these treatments target the metal-prion relationship.
Clioquinol is a Cu/Zn/Fe chelator of low affinity and been shown to offer a considerable
benefit in preventing Aβ containing plaques in mice infected with Alzheimer’s disease. It has
also been tested as a metal-attenuating therapeutic in animal models of transmissible spongiform
encephalopathies. Clioquinol chelates zinc and copper and acts as an antioxidant. Unsaturated
lipids are partially susceptible to oxidative modification, and lipid peroxidation is a marker of
oxidative stress. Reactions of H2O2 with redox active metals like copper and iron, release a
powerful oxidant. A study by Bareggi et al. looked at the effects of clioquinol on the changes in
motor and cognitive behaviors and effects on amyloid deposition in mice infected with scrapie.
Fifty 20-day old female hamsters weighing about 60 g were studied, and the treatment group was
inoculated on the right hemisphere with 25µL of scrapie 263 K prions (diluted in saline). The
treatment group received 0.5mg/g clioquinol by a feeding pellet incorporated into its diet.
Passive avoidance behavior was tested using a series of foot shocks and showed that mice treated
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with clioquinol improved passive avoidance similar to those observed by the non-infected
control mice. Oxidative stress increased in the infected animals and peaked 60 days after
infection. The study showed that Clioquinol counteracts massive memory deficit induced by
scrapie infection, but Western blot, immunohistochemistry, histopathological and neurochemical
findings showed that it did not reduce PrP deposition or synapse loss. This further indicates that
the beneficia effects of clioquinol is due to its antioxidant effects (Bareggi et al., 2009).
A report by Brazier et al. detected a reduction of total superoxide dismutase (SOD)
activity in mice infected with PrP, and greater Mn-SOD activity than wild type mice. Brazier et
al. studied the therapeutic efficacy of EUK-189 (Eukarion salen-manganese complex) as an
antioxidant compound. Daily intraperitoneal (ip) administration of EUK-189 was found to
extend the incubation period, reduce nitrative and oxidative damage to proteins, and reduce brain
vacuolar lesion burden, compared to untreated disease-controlled mice. Thirty-five young female
mice were intra-cerebrally inoculated with a mouse adapted prion that was originally isolated
from a human patient. The control infected mice survived an average of 169 dpi while the EUK189 treated mice survived an average of 177 dpi. Lipid peroxidation, protein carbonylation, and
tyrosine nitration were studied to see the effects of oxidative stress. Reduced oxidative stress was
seen for all tests in the EUK-189 treated mice compared to the untreated disease control mice.
This study supports the idea that oxidative stress is an integral component of pathogenesis
(Brazier et al., 2008).
A 2010 study with Brazier et al. in 2010 showed that manganese chelation therapy has
been seen to extend survival in mice. The di-sodium, calcium derivative of the chelator
cyclohexanediaminetetraacetic acid (Na2CaCDTA) was administered intraperitoneally to mice
inoculated intra-cerebrally with either high or low dose inocula. This chelator has been shown to
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bind and remove Mn2+ from the brains of experimental animals. Analysis by inductively coupled
plasma-mass spectrometry revealed brain Mn2+ levels were reduced up to 50% in treated mice
compared to the treated control (copper, iron, zinc, cobalt level remained unchanged). The mice
that received a high-dose inocula did not display increased survival, but Western blot analysis of
intensely treated mice showed reduced PrPSc levels. Survival time was only extended by
approximately 12%, which is a modest result compared to other findings. These mice were
infected with the M1000 strain, which is of human origin, and may indicate that different strains
require different therapeutic strategies (Brazier et al. 2010).
Conclusion
Prions diseases include a variety of human and animal diseases that are
neurodegenerative and affect the central nervous system. The infectious agent of these diseases is
the prion protein (PrPSc), which begins to form aggregates in the brain when normal PrPC is
converted from its alpha structure to the infectious beta structure that is unable to be broken
down in the brain. Although rare, there is potential for these diseases to increase in incidences,
especially with forms such as sporadic CJD in humans. The mechanism for infection and the
pathways in which this conversion occurs has not been well established. In attempts to
understand the pathway, recent studies have suggested that metals within the body affect the PrP
protein and its way of infection. Many of these experiments were conducted on animals using a
form of human PrP and have showed that zinc, copper, iron, and manganese each play a role in
infection. These transition metals within the body bind and interact with PrP when tested at
different levels, suggesting that when metals get out of homeostasis range there is an increased
risk of infection. As seen, these metals can cause PrP to affect other cell processes, metal
homesostasis can affect oxidative stress, the presence/absence of metal can affect PrP structure,
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and aggregate formation requires metal. Because these metals interact with PrP, it has also been
suggested that targeting these metals may serve as a treatment strategy. No one metal seems to
solely be responsible for the conversion of PrP, as zinc, copper, iron, or manganese, each have
the ability to do so. Additionally, this area is limited in the number of publications. Taken
together, these findings point to an increased need for research to fully understand the role metals
play on PrP and prion diseases.
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